Shots: Fulcrum to receive $10M upfront, reimbursement for R&D costs, research, development and commercial milestone of up to $295M for first product commercialized and additional payments $143.5M for all subsequent […]readmore
Tags : Agreement
Shots: Gilead collaborates with Eisai to distribute & co-promote filgotinib for RA. Gilead will be accountable for manufacturing and approval of filgotinib while Eisai will be responsible for distribution in […]readmore
Shots: Rhoes to receive $42.5M up front, milestones $90M for specified research and preclinical development plus option fees, $660M milestones based on development, regulatory and sales plus royalties on sales. […]readmore
Shots: Sarepta to receive $1.15B up front including $750M in cash $400M in Sarepta stock, priced at $158.59/share of common stock, up to $1.7B regulatory and sales milestones plus royalties […]readmore
Shots: UVA in collaboration with Novo Nordisk to co-develop virtual patient modeling for T2D patients. The collaboration will utilize UVA’s work and insights on patient simulation and data-driven models within […]readmore
Shots: Ionis to get $45M as license fee, additional milestone up to $155M plus royalties on sales and will also be responsible for P-I trial assessing IONIS-MAPTRx in patients with […]readmore
Shots: Akcea retains exclusive rights to develop and commercialize AKCEA-APOCIII-LRx following Novartis’ decision for not exercising the option In 2017, Novartis signed an option agreement with Akcea for two antisense […]readmore
Shots: Onconova to get clinical, regulatory and sales-based milestones up to $30.4M and royalties on sales. Specialised to receive exclusive rights to commercialize rigosertib in Australia and New Zealand The […]readmore
Shots: Scripps Research to receive up front, development & commercialization milestones, option exercise fee and royalties on sales of new therapies and will conduct pre-clinical R&D activities and P-I studies […]readmore
Shots: AstraZeneca collaborates with Gatehouse Bio to explore new targets for respiratory and CV diseases utilizing Gatehouse Bio’s AI-powered sRNAlytics platform The collaboration allows Gatehouse Bio to develop next-generation therapies […]readmore